Highest-materiality recent filing
CervoMed reports Q1 2026 net loss of $8.0M; cash runway only into Sept 2026
Net loss $8.0M vs $4.9M YoY; no grant revenue vs $1.9M prior year.
CervoMed: neflamapimod increases basal forebrain volume in DLB Phase 2b MRI analysis
At week 16, right BF volume increased 3.5% with neflamapimod vs -4.2% with placebo (p=0.028).
CervoMed presents neflamapimod Phase 3 design and MRI data at LBD Annual Meeting
New MRI analyses from Phase 2b RewinD-LB trial show neflamapimod may reduce basal forebrain atrophy in DLB.
CervoMed Phase 2b DLB data show greater benefit in patients without AD co-pathology
At pTau181 <21 pg/mL, neflamapimod showed CDR-SB improvement of -1.11 vs placebo (p=0.005) in within-participant analysis.
FY2025 net loss $27.0M vs $16.2M; cash $20.9M (down from $38.9M), sufficient for ~6 months.
CervoMed selects 50mg TID neflamapimod dose for Phase 3 DLB trial after Phase 1 PK study
Phase 1 healthy volunteer study completed evaluating PK of a new stable crystal form of neflamapimod.
CervoMed's neflamapimod selected for UK EXPERTS-ALS platform for ALS trial
Neflamapimod will be evaluated in EXPERTS-ALS, funded by UK NIHR and motor neuron disease charities, costs covered externally.
Neflamapimod slows DLB progression in Phase 2b; 89% worsening reduction in key subgroup
Primary endpoint CDR-SB mean change 52% lower with DP Batch B vs control; 82% lower in patients without AD co-pathology.
CervoMed reports Q3 2025 net loss $7.7M; FDA aligned on Phase 3 trial design for neflamapimod in DLB
Net loss of $7.7M for Q3 2025 vs $4.8M in Q3 2024; cash $27.3M at Sept 30, 2025.
CervoMed gets FDA alignment on Phase 3 trial design for neflamapimod in DLB
FDA aligned on primary endpoint (CDR-SB), patient enrichment strategy, and trial design for ~300 DLB patients.
CervoMed new Phase 2b data: neflamapimod improves CDR-SB in DLB subgroup, reduces GFAP biomarker
In DLB patients with low AD co-pathology (ptau181<21 pg/mL), neflamapimod showed significant improvement on CDR-SB (p=0.005) in within-subject comparison to placebo.
CervoMed reports Q2 loss $6.3M; neflamapimod shows 54% risk reduction in DLB extension phase
Net loss of $6.3M for Q2 2025 vs $2.3M loss a year ago; cash $33.5M as of June 30, 2025.
CervoMed reports neflamapimod 54% risk reduction on CDR-SB at Week 32 in DLB trial
At Week 32, neflamapimod showed 54% risk reduction in >=1.5-point CDR-SB worsening vs control (p=0.0037); 64% in ptau181<2.2 patients (p=0.0001).
CervoMed posts Q1 net loss $4.9M, secures $50M ATM facility; reports positive Phase 2b DLB results
Entered $50M at-the-market offering agreement with Leerink Partners; 3% commission on sales.
CervoMed appoints EVP Clinical Development and EVP Regulatory; COO Cobuzzi to depart July 1, 2025
Kelly Blackburn promoted to EVP Clinical Development (previously SVP), effective April 16, 2025; base salary $448,360, target bonus 35%.
CervoMed reports positive Phase 2b extension data for neflamapimod in DLB
Neflamapimod slowed clinical progression on CDR-SB vs old capsules (p<0.001) and vs placebo (p=0.003) over 16 weeks.
CervoMed reports Q4/FY2024 results; positive Phase 2b extension data for neflamapimod in DLB
Cash $38.9M at Dec 31, 2024 (up from $7.8M); funded into mid-2026.
CervoMed announces positive Phase 2b extension results for neflamapimod in DLB
New capsule batch yielded higher plasma levels; CDR-SB improved vs old capsules (p<0.001) and vs placebo (p=0.003).
No discernible differences between neflamapimod 40mg TID and placebo during 16-week double-blind phase of RewinD-LB trial.
Neflamapimod did not demonstrate statistically significant effects vs placebo on CDR-SB, TUG, NTD, or CGIC at 16 weeks.
CervoMed reports Phase 2a biomarker data for neflamapimod in DLB; RewinD-LB topline due Dec 2024
Plasma GFAP significantly reduced by neflamapimod (p=0.015 vs placebo); reductions linked to clinical improvement.
CervoMed to present RewinD-LB Phase 2b data at ILBDC Jan 2025; topline due Dec 2024
Oral presentation of detailed safety/efficacy results from neflamapimod Phase 2b in DLB at ILBDC on Jan 31, 2025.
CervoMed completes last patient visit in Phase 2b DLB trial; topline data expected Dec 2024
Last patient last visit completed in Phase 2b RewinD-LB trial evaluating neflamapimod in early-stage DLB.
CervoMed reports Q2 2024 net loss $2.3M, cash $50.9M; DLB trial enrolled, topline Dec 2024
Net loss $2.3M in Q2 2024 vs $1.4M in Q2 2023; operating loss $3.0M vs $1.2M.
CervoMed presents Phase 2a biomarker data at AAIC; neflamapimod reduces plasma GFAP in early DLB
Poster at AAIC 2024: baseline plasma GFAP highly correlated with CDR-SB dementia severity in DLB patients.
CervoMed completes enrollment in Phase 2b neflamapimod trial for DLB; topline data due Dec 2024
Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB) fully enrolled.
CervoMed names William Elder as CFO; William Tanner departs to consulting role
William Elder appointed CFO effective June 1, 2024, succeeding William Tanner; Elder continues as General Counsel and Corporate Secretary.
CervoMed reports Q1 net income $2.5M; DLB trial enrollment on track for Q2 2024
Cash $6.4M as of March 31; plus $50M upfront from private placement closed April 1 provides runway through end 2025.
CervoMed posts 2023 net loss of $2.2M; secures $50M private placement; Phase 2b DLB trial on track
Net loss $2.2M for 2023; cash $7.8M as of Dec 31, 2023; R&D spending increased to $8.4M.
CervoMed secures $50M upfront private placement; warrants could add $99.4M; funds Phase 2b DLB trial
Gross proceeds ~$50M upfront; up to ~$149.4M if Series A warrants ($39.24/share, 100% premium) fully exercised.
In pure DLB patients, neflamapimod reduced GFAP by mean 10.6 pg/mL vs 14.1 increase with placebo (p=0.04).
appointed William Elder, the Company’s current General Counsel, Corporate Secretary and Acting Principal Financial Officer, to serve as the Company’s Chief Financial Officer, effective June 1, 2024.
Dr. Tanner’s employment with the Company will terminate effective May 31, 2024, and, effective June 1, 2024, Dr. Tanner will begin service as a consultant to the Company.
Max materiality 0.90 · Median 0.65 · Most common event other_material